Clinical Trials
62 trialsPD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC
Sun Yat-sen University
Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC
Jiangxi Provincial Cancer Hospital
PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer
Sun Yat-sen University
PILOT
The Affiliated Hospital of Qingdao University
IMPROVE
Fudan University
RAIC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer
Sun Yat-sen University
Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
The First Hospital of Jilin University
Ablation Combined With PD-1 in HCC: Phase II Study
Sun Yat-sen University
A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
CONTINUUM
Sun Yat-sen University
Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer
Sun Yat-sen University
Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma
Guilin Medical University, China
Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors
Renmin Hospital of Wuhan University
A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer
Shanghai Celfuture Biotech Co., Ltd.
PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial
The First Affiliated Hospital of Zhengzhou University
PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery
Fudan University
neoSCORE
Second Affiliated Hospital, School of Medicine, Zhejiang University
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer
Massachusetts General Hospital
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer
Beijing 302 Hospital
RISE-HN
National Taiwan University Hospital
Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL
ChineseAMS
PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
Beijing Friendship Hospital
Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL
ChineseAMS
Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma
China Medical University, China
SEHC
The First Affiliated Hospital of Soochow University
NEOSUN
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy
Blokhin's Russian Cancer Research Center
Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer
Ruijin Hospital
a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors
Taizhou Hanzhong biomedical co. LTD
Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer
Hangzhou Cancer Hospital
PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients
Sun Yat-sen University
An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer
Chinese PLA General Hospital
SPENT
Sun Yat-sen University
Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer
Zhejiang Cancer Hospital
Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer
Fudan University
The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer
Fudan University
Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors
Henlix, Inc
Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma
West China Hospital
Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
Beijing Tongren Hospital
CCRT+PD-1
Peking University Third Hospital
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
Xiangya Hospital of Central South University
Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma
Beijing Tongren Hospital
Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma
Ruijin Hospital
PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer
Fujian Cancer Hospital